683 Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

683 Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$19K	–	329
2022 Q3	$19K	Hold	10,000	–	–	﹤0.01%	195
2022 Q2	$37K	Hold	10,000	–	–	﹤0.01%	212
2022 Q1	$65K	Hold	10,000	–	–	﹤0.01%	299
2021 Q4	$117K	Buy	+10,000	New	+$151K	﹤0.01%	297

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

683 Capital Management's TSHA Position: Q4 2022 in Review

683 Capital Management sold out of Taysha Gene Therapies (TSHA) in Q4 2022, closing a stake of 10,000 shares — an estimated $19K sold.

683 Capital Management first reported a position in TSHA in Q4 2021 and held it in 4 quarters. The position peaked at $117K in Q4 2021. 52 funds tracked by Wall St. Rank hold TSHA as of Q4 2022.

683 Capital Management reported no remaining Taysha Gene Therapies position as of Q4 2022 after selling out during the quarter.
683 Capital Management sold 10,000 Taysha Gene Therapies shares in Q4 2022, an estimated $19K.
683 Capital Management first reported a position in Taysha Gene Therapies in Q4 2021 and held it in 4 quarters.
683 Capital Management's Taysha Gene Therapies position peaked at $117K in Q4 2021.
52 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2022.

Based on 683 Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.